Cytosorbents (CTSO) Q2 2024 earnings summary

Executive summary

• Q2 2024 total revenue increased 5% year-over-year to $9.9M, driven by a 10% rise in product sales and strong global adoption, while grant income declined.

• Operating loss reduced by 48% to $3.4M, reflecting cost reductions, operational efficiencies, and lower R&D and consulting expenses.

• Over 250,000 devices delivered globally, marking a major milestone and positive user feedback on new products.

• Workforce reduced by 17% over five months, with further cost cuts expected to save $5M annually.

• CFO transition announced, with Peter J. Mariani replacing retiring Kathleen Bloch.

Financial highlights

• Q2 2024 product sales reached $8.8M, up 10% year-over-year; grant income declined to $1.1M.

• Gross margin on devices and accessories improved to 75% in Q2 2024 from 74% in Q2 2023.

• First half 2024 product revenue was $17.8M, up 12% year-over-year; total revenue was $19.7M, up 4%.

• Cash and equivalents (including restricted) at quarter-end totaled $14.9M, with $8.5M unrestricted.

• Net loss for Q2 2024 was $4.1M, improved from $6.2M in Q2 2023; net loss per share was $(0.08).

Outlook and guidance

• On track to submit DrugSorb-ATR marketing applications to FDA and Health Canada in Q3 2024, with FDA prioritized.

• Unrestricted cash expected to fund operations through Q2 2025, contingent on achieving milestones to unlock restricted cash.

• Additional $10M from Avenue Capital credit facility available upon meeting requirements; further capital may be needed if milestones are not met.

• Cost-cutting measures expected to save $5M annually and further improve gross margin with higher volumes.

• If approved, DrugSorb-ATR could address a $325M initial market in U.S. and Canada.